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New findings: 
• What is the topic of this review?  
This review summarizes the evidence on sodium glucose transporter 3 (SGLT3) localization, 
electrophysiological properties, agonist specificity, and its putative physiological role. 
• What advances does it highlight? 
Published information is reviewed in some detail by comparing human and rodent isoforms, 
as well as advances in testing hypotheses for its physiological role as a glucose sensor or 
incretin release mediator. We provide a critical overview of available published data and 
discuss a putative functional role for SGLT3 in human and mouse physiology. 
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Abstract 
Sodium glucose transporter 3 (SGLT3) has attracted interest because of its putative role as a glucose 
sensor, rather than a sugar transporter, in contrast to its SGLT1 and SGLT2 co-family members. 
Significant progress has been made in characterizing the electrophysiological properties in vitro of 
the single human SGLT3 isoform and the two mouse isoforms, SGLT3a and SGLT3b. Although early 
reports indicated SGLT3 expression in the small intestinal myenteric and submucosal neurones, 
hypothalamic neurones, portal vein, and kidney, a lack of reliable antibodies has left unanswered its 
exact tissue and cellular localization. Several hypotheses for a role of SGLT3 in glucose sensing, 
gastric emptying, GLP-1 release, and post-Roux en-Y gastric bypass remodelling have been explored, 
but so far there is only limited and indirect supportive evidence using non-specific 
agonists/antagonists, but with no firm conclusions. There are no published or available data in 
knockout animals and translation is difficult because of its different isoforms in human versus rodent, 
as well as a lack of selective agonists or antagonists, all making SGLT3 challenging to study. However, 
its unique electrophysiological properties, ubiquitous expression at the mRNA level, enrichment in 
the small intestine, and potential, but uncertain, physiological role demand more attention. The 
purpose of this overview and review of SGLT3 biology is to provide an update, highlight the gaps in 
our knowledge, and try to signpost potential ways forward to define its likely function in vivo. 
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Introduction 
The SLC5 family is exemplified by the SGLT1 isoform (Slc5a1) that is responsible for active glucose 
absorption in the intestine, but is also present in the kidney proximal tubule, and the SGLT2 isoform 
(Slc5a2) that is almost exclusive to the renal epithelium and is responsible for the bulk of glucose 
reabsorption by the kidney. SGLT2 has become topical recently, because it is an effective therapeutic 
target for lowering blood glucose levels in poorly controlled diabetes mellitus. Targeting this 
transport pathway in the kidney has been approved by some authorities as a second-line therapy in 
type 2 diabetes after metformin. However, the advances in SGLT1 and SGLT2 biology and function 
have been reviewed comprehensively elsewhere (Poulsen et al., 2015; Song et al., 2016; Lehmann & 
Hornby, 2016) and in the present review we focus on recent developments in our understanding of 
the distribution and function of another SLC5 family member and putative glucose sensor, SGLT3. Its 
function and topographical distribution have been less well studied and are still incompletely 
defined. We review its gene structure, electrophysiological and transport properties, differences 
between human and rodent isoforms, tissue and cellular distribution, and putative physiological 
role(s). Finally, we will emphasize the gaps in current knowledge and outline some future 
perspectives. 
 
SGLT3 (Slc5a4) 
Structure  
Human SLC5A4 gene is located on chromosome 22 at locus 22q12.3. The gene contains 17 exons; 
SLC5A1 coding SGLT1 is close by on the same chromosome. In contrast, rat and mouse have 2 
isoforms, Slc5a4a and Slc5a4b. In rodents both isoforms are in close proximity on the same 
chromosome, chromosome 10 and 20 in the mouse and rat, respectively. So far, mouse and rat are 
the only species known to have 2 isoforms of Slc5a4, making it more difficult to extrapolate findings 
from rodent models to human. Human SGLT3 cDNA was fully cloned by Diez-Sampedro et al. in 2003. 
In mouse the SGLT3b isoform was the first to be cloned (Tabatabai et al., 2003), followed by SGLT3a, 
and then rat SGLT3a (Barcelona et al., 2012). Rat SGLT3b has not been fully cloned and its sequence 
is predicted from the genomic sequence. 
The identity of the amino acid sequence of SGLT3 is about 70% compared with SGLT1, and 55-60% 
compared with SGLT2 in each species (see Table 1). Interestingly, mouse and rat SGLT3a isoforms are 
closer (79-80%) to human SGLT3 than SGLT3b isoforms (76%). Basic phylogram analysis confirmed a 
closer relationship of mouse and rat SGLT3a isoforms to human SGLT3. Consistent with this, amino 
acid residues in the conserved ligand binding sites of rodent SGLT3a isoforms are more similar to 
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human SGLT3 (only residue F101 in the outer gate is different - Table 2), suggesting a distinct 
functional role of the two rodent isoforms. Indeed, mSGLT3b is able to partially transport glucose in a 
similar way to SGLT1. In contrast, mSGLT3a does not transport glucose or generate currents at pH 7.4 
(Barcelona et al., 2012). That these rodent isoforms may have distinct roles is also consistent with the 
high level of identity between the corresponding mouse and rat SGLT3a (93%), and SGLT3b (90%) 
isoforms, respectively, while identity between the SGLT3a and SGLT3b isoforms for mouse and rat is 
only about 75%. Similarly, conservation in the ligand bindings sites is very high between rat and 
mouse isoforms (Table 2). 
Based on in silico predictions and the solved crystal structure of the Vibrio parahaemolyticus 
sodium/galactose symporter (vSGLT), SGLT proteins are composed of 14 transmembrane helices 
(Faham et al., 2008). Actual structural differences between SGLT3 and other isoforms are not known, 
but the key amino acid in the sugar-binding site has been identified. In isoforms able to transport 
glucose (SGLT1 and 2), the residue within TM11 in the position 457 is glutamine. In contrast, SGLT3 
isoforms that do not transport glucose have glutamate at this position (Table 2), except for the 
SGLT3b isoform of mouse and rat, which can partially transport glucose and has glycine or serine, 
respectively. Indeed, it was shown experimentally that in both hSGLT3 and mSGLT3a a change of 
glutamate to glutamine restored the ability of the protein to transport the glucose analogue α-MDG 
in a Na+-dependent manner, and resulted in similar apparent affinities for glucose analogues to 
hSGLT1. Similarly, mutated hSGLT1 with glutamate at the position where glutamine is normally 
present loses the coupling to Na+ and has a lower K0.5 than wildtype hSGLT1 (Díez-Sampedro et al., 
2001; Bianchi & Díez-Sampedro, 2010; Barcelona et al., 2012). The glutamine at position 457 in 
SGLT1 is also important for binding of the competitive SGLT inhibitor phlorizin, since mutated hSGLT3 
with glutamine instead of glutamate (E457Q-hSGLT3) exhibits 100x higher affinity for phlorizin 
(Bianchi & Díez-Sampedro, 2010). Interestingly, there is full conservation at the Na+ binding residues 
between SGLT1 and SGLT3 (Table 2). The difference in F453 in SGLT3a isoform in the outer gate, 
which closes after sugar binding and makes the sugar binding site inaccessible (Sala-Rabanal et al., 
2012), may be responsible for the inability of SGLT3a to transport sugars. 
 
Tissue distribution and localization 
In humans, mRNA expression screening revealed highest SGLT3 expression in the small intestine, 
followed by significant expression in skeletal muscle and testis. However, mRNA has also been 
detected at lower levels in many other tissues, including adrenal gland, bone marrow, heart, kidney, 
lung, prostate, spinal cord, stomach, thyroid gland, trachea, uterus, brain, and blood vessels 
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(Nishimura & Naito, 2005; Chen et al., 2010). Expression has also been detected in several human 
colonic and ovarian cancers, and in various cancer cell lines (Veyhl et al., 1998). 
Human SGLT3 protein has been detected by western blotting and immunohistochemistry in small 
intestine, skeletal muscle, and kidney (Diez-Sampedro et al., 2003). Immunofluorescence staining 
localised the protein to discrete patches in the submucosa of the small intestine, which co-localized 
with the nicotinic acetylcholine receptor, suggesting hSGLT3 expression is in cholinergic neurones of 
the submucosal and myenteric plexus. Moreover, similar co-localization was found at the 
neuromuscular junction of skeletal muscle (Diez-Sampedro et al., 2003). SGLT3 protein has also been 
reported in human kidney homogenates and the HK-2 proximal tubule cell line (Kothinti et al., 2012). 
Of note, there is a discrepancy between the sizes of the bands detected by these groups. Diez-
Sampedro et al. (2003) detected the band at ~60kDa, which is smaller than the predicted protein size 
(72 kDa) that was detected by the other group in kidney (Kothinti et al., 2012). The antibodies of both 
groups were made to order and raised against very similar peptides with 95% shared sequence 
homology. Nevertheless, both groups did provide appropriate controls using over-expressing cell 
line/oocytes, empty vectors, blocking peptides, and negative cross-reactivity with SGLT1. 
In mouse and rat, mRNA expression of SGLT3a and SGLT3b seems to be broadly similar. Using reverse 
transcriptase PCR both isoforms have been found in mouse small intestine and kidney (Gribble et al., 
2003; Tabatabai et al., 2003). Quantitative PCR revealed much higher mRNA expression of SGLT3a 
and SGLT3b in small intestine compared with kidney (~150,000- and 700-fold, respectively) 
(Barcelona et al., 2012). In the hepatic portal area, which itself is not well defined and includes the 
portal vein, hepatic artery and common bile duct, the expression levels for both isoforms were 
similar to levels found in the kidney, with SGLT3a ~4 times higher than SGLT3b (Delaere et al., 2013). 
The first attempt to profile SGLT3 mRNA expression in rat intestine was reported by Freeman et al. 
(2006). The authors detected transcripts in duodenum, jejunum, and colon, with relatively similar 
levels detected in each segment. However, the primers and probe sequence for SGLT3 were based on 
the human sequence for SLC5A4, and although it shared substantial similarities with rat, it cannot 
distinguish between the rodent SGLT3a and SGLT3b isoforms. Studies designed to differentiate 
between the two isoforms have detected expression in hypothalamus, kidney and duodenum in 
Sprague-Dawley rats (O’Malley et al., 2006), while SGLT3b was also detected in jejunum and proximal 
ileum (Pal et al., 2015). In addition, SGLT3b was detected in different parts of the jejunum after Roux-
en-Y gastric bypass (RYGB) surgery in Sprague-Dawley and Zucker diabetic fatty (ZDF) rats (Bhutta et 
al., 2014). In cell lines, expression was found in the intestinal endocrine GLUTag cell line (Gribble et 
al., 2003) and in primary cultures of mouse cortical kidney cells (Tabatabai et al., 2001). Overall, from 
published microarray datasets reporting expression across most tissues, it is clear that the highest 
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expression occurs in the small intestine for both isoforms. Low-level expression is detected in most 
other tissues with moderate expression of SGLT3b occurring in testes and ovary (GEO datasets: 
GDS3142, GDS3357, GDS4319). 
In rodents there are limited data on SGLT3 at the protein level. It has been localized by western blot 
to kidney, liver, ileum, and portal vein area. However, the specificity of the antibody is uncertain, 
because the authors interpreted two bands of 71 and 72kDa as staining for both SGLT3a and SGLT3b 
isoforms, but did not describe how the antibody was generated (Delaere et al., 2013). SGLT3 has also 
been detected by western blot in various brain structures, including cortex, hypothalamus, 
hippocampus, midbrain, striatum, medulla, olfactory bulb, and cerebellum (Yamazaki et al., 2014). 
The antibody used was raised against the peptide for mouse SGLT3b and again the authors could not 
distinguish between the SGLT3a and SGLT3b isoforms. Using immunofluorescence, the authors 
detected SGLT3 in neurones, but not astrocytes of the striatum and cortex; detection was performed 
using another SGLT3 antibody, although details of its specificity were not provided. However, the 
staining strongly co-localized with choline acetyltransferase, which is consistent with the co-
localization of hSGLT3 and the β-subunit of acetylcholine receptor reported in human skeletal muscle 
and intestine (Diez-Sampedro et al., 2003), suggesting that cholinergic neurones are an important 
site of mSGLT3 protein localization. While, neuronal localization is likely in these tissues, wider 
neuronal localization has not been explored.  
Taken together, the highest expression among tissues is convincingly reported at the mRNA level in 
different regions of the small intestine. Ubiquitous expression at low levels seems to be present in 
most tissues, with possibly more significant expression in ovaries, testis, and skeletal muscle. Though 
expression has been detected in kidney, its level seems to be very low and the localization of mRNA 
expression to specific cell types is lacking. Western blotting has revealed SGLT3 protein in small 
intestine, kidney, brain structures, liver, and portal vein area. Human SGLT3 protein has been 
localized to cholinergic neurones of the small intestine submucosal and myenteric nerve plexuses, 
and neuromuscular junction of skeletal muscle. In mouse, cholinergic neurones of brain cortex and 
striatum also show positive immunofluorescence staining. However, localization data at the protein 
level needs to be considered with some caution, since the antibodies used do not always show 
convincing specificity or distinguish between isoforms, and additional studies on cellular localization 
are required. The expression of all isoforms is summarized in Table 3.   
 
Functional properties 
Functional studies in Xenopus laevis oocytes expressing human SGLT3 showed that hSGLT3 does not 
transport glucose in the absence or presence of Na+ at pH 7.5 or 5 (Diez-Sampedro et al., 2003); 
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however, D-glucose and α-MDG were able to generate a phlorizin-sensitive, Na+-dependent 
depolarization of oocyte cell membrane potential, while D-galactose, D-fructose, and mannitol had 
no effect. The glucose-induced depolarization shows saturation with a K0.5 of 20 mM and a maximum 
depolarization of 23 mV, increasing as resting membrane potential is lowered (Diez-Sampedro et al., 
2003). No glucose/α-MDG-induced currents were observed in the absence of Na+ at pH 7.4, although 
glucose/α-MDG-induced currents are substantially greater at lower pH (pH 5) when the charge 
carrier is likely to be H+. In addition, at low pH, glucose/α-MDG is able to induce currents even in Na+-
free media. This is supported by the observation that there is no increase in Na+ uptake at pH 5, but 
there is significant intracellular acidification, consistent with H+ as the charge carrier at low pH. 
Interestingly, the imino sugars, 1-deoxynojirimycin (DNJ), N-hydroxylethyl-1-deoxynojirimycin 
(miglitol), and N-butyl-1-deoxynojirimycin (miglustat), which are all potent inhibitors of α-glucosidase 
enzymes of the intestinal brush border membrane, are potent agonists at hSGLT3 with a K0.5 of 0.5 - 5 
µM, which is up to a 40,000 times greater affinity than for glucose (Voss et al., 2007). However, imino 
sugars are not of mammalian origin and are not expected to be the natural agonists. Nonetheless, it 
provides a pharmacological tool to study a functional role of SGLT3, although their higher affinities 
for α-glucosidases prevent their use as specific agonists, at least in the small intestine. 
In rodents, the two isoforms of SGLT3 exhibit different electrophysiological properties, as well as 
different responses to glucose and glucose analogue-induced stimulation. At pH 7.4 in the presence 
of Na+, mSGLT3a expressed in oocytes does not depolarize the cell membrane when exposed to D-
glucose, α-MDG, or DNJ, unlike with hSGLT3. In contrast, at pH 7.4 glucose, α-MDG, 1-deoxyglucose, 
and 6-deoxyglucose induce a strong depolarization in mSGLT3b-expressing oocytes (Aljure & Díez-
Sampedro, 2010; Barcelona et al., 2012). Like mSGLT3a, mSGLT3b is also not activated by DNJ, but 
unlike hSGLT3 and mSGLT3a, mSGLT3b is able to transport sugar to a small extent, although the 
uptake of the glucose analogue α-MDG is about 60 times less than uptake by mSGLT1 (Aljure & Díez-
Sampedro, 2010). In addition, mSGLT3b shows only a small pH-dependency; glucose-induced 
currents are present at neutral and acidic pH (Barcelona et al., 2012). Rat SGLT3a exhibits similar 
functional properties to mSGLT3a. Oocytes expressing rSGLT3a exposed to glucose showed minimal 
currents at pH 7.4, but inward currents are much larger at lower pH, and in the presence of glucose 
(Barcelona et al., 2012). These characteristics of mSGLT3a, and mSGLT3b in oocytes have been 
confirmed in mammalian CHO (Chinese Hamster Ovary) cells expressing these isoforms (Barcelona et 
al., 2012). It seems that in rodents the properties of the SGLT3 isoforms can be separated according 
to external pH; however, the significance of this in vivo is unknown. 
Overall there are substantial differences between human and rodent SGLT3 electrophysiological 
characteristics that are summarized in Table 4. While hSGLT3 does not transport glucose, it can 
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induce a small depolarization at pH 7 and it is pH-sensitive. In contrast, mouse and rat SGLT3a do not 
respond to glucose at pH 7, but at low pH can generate currents carried most probably by H+, and 
these glucose-induced currents are larger than those for H+ alone. In contrast, mSGLT3b can 
transport glucose and generates currents in response to glucose, rather than H+. 
 
Physiological role 
Although the electrophysiological properties of human and mouse SGLT3 have been well described, 
their physiological function is unknown. The inability of SGLT3 protein to transport glucose (or its 
analogues) and its ability to generate membrane currents in the presence of glucose and Na+ or H+ 
have led to the hypothesis that SGLT3 might act as a glucose sensor. Another hypothesis is that 
SGLT3 controls gastric emptying, which may be related to the pH-dependency of SGLT3’s membrane 
current generation (see earlier): chyme released from the stomach will progressively lower duodenal 
luminal pH (Miller et al., 1978) causing SGLT3 to generate larger currents at this lower pH. 
Intraduodenal perfusion of glucose and its analogues 3-O-methylglucose (3-OMG), and α-methyl-D-
glucose (α-MDG) can inhibit gastric emptying in conscious rats, while 2-deoxyglucose (2-DG, a 
substrate for facilitative glucose transporters) cannot (Freeman et al., 2006). In addition, 
intraduodenal perfusion with glucose inhibits gastric motility in anesthetised rats, while galactose has 
the opposite effect. The authors (Freeman et al., 2006) used the difference in glucose and galactose 
affinity for SGLT1 and SGLT3 - both glucose and galactose are substrates of SGLT1, whereas galactose 
has negligible affinity for SGLT3 (Díez-Sampedro et al., 2000; Voss et al., 2007) - to conclude that 
SGLT3 delays gastric emptying. However, the low affinity of galactose for hSGLT3 was seen at pH 7.4, 
whereas galactose’s ability to induce currents via mSGLT3a at pH 5 is similar to glucose and other 
glucose analogues (Barcelona et al., 2012). While the same authors consider 3-OMG and α-MDG as 
substrates for both SGLT1 and SGLT3, others have reported data showing 3-OMG is not a substrate 
for pig SGLT3 (Díez-Sampedro et al., 2000) and interpret the difference between 3-OMG and α-MDG 
to distinguish the effects between SGLT1 and SGLT3 in rat (Delaere et al., 2013; Pal et al., 2015). 
Thus, the interpretation of SGLT3 as a mediator of gastric emptying by Freeman et al. (2006) seems 
less certain. 
The role of SGLT3 as a glucose sensor has also been proposed and tested in the hepatic portal vein of 
the rat (Delaere et al., 2013). Detection of glucose in hepatic portal vein after protein-enriched, diet-
induced intestinal gluconeogenesis has been shown to decrease food intake (Mithieux et al., 2005). 
Delaere and colleagues (2013) excluded GLUT2 and taste receptors as mediators of the sensing 
mechanism and proposed SGLT3 as the sensing mediator. They showed that glucose or αMDG 
infusion reduced food intake, while 3-OMG did not. The effect of glucose on food intake was 
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abolished by phlorizin and following exposure of the portal vein to capsaicin to denervate sensory 
nerves. The effect of glucose was not changed after ventral vagotomy. SGLT3 mRNA and protein 
were detectable in the portal vein area; however, the reported mRNA levels were similar to those 
found in kidney, which are much lower than in intestine (unpublished observations). Since the 
presence of SGLT3 can be detected, and sensory afferents are involved, and because 3-OMG is not a 
substrate for SGLT3, at least in pig, these authors concluded that SGLT3 is the portal glucose sensor.  
The main glucose sensing mechanism in the body that leads to insulin secretion depends on closure 
of KATP channels in pancreatic beta cells. A similar mechanism has been proposed for glucose-
stimulation of neurones. However, only a small proportion (9%) of cultured hypothalamic glucose-
stimulated neurones show any response to the K+ channel inhibitor tolbutamide (O’Malley et al., 
2006), suggesting that other mechanisms exist. The majority of glucose-excitable cultured 
hypothalamic neurones show a rise in cytosolic Ca2+ in response to the αMDG, a substrate of the 
SGLTs, but not the GLUTs; an effect blocked by phlorizin (O’Malley et al., 2006). A higher proportion 
of neurones are activated by αMDG (67%) than by 3-OMG (45%). This difference may be accounted 
for by SGLT3 and is supported by the finding of SGLT3a and SGLT3b expression in rat hypothalamus 
and cultured hypothalamic neurones (O’Malley et al., 2006). Moreover, hSGLT3 expressed in sensory 
neurons of C. elegans is able to mediate preferential glucose-induced chemotaxis in low pH and this 
effect is blocked by phlorizin (Bianchi & Díez-Sampedro, 2010). In addition, glucose and DNJ, an 
hSGLT3 agonist, activate rat intestinal enterochromaffin cells and myenteric neurons (Vincent et al., 
2011). 
 
Roux-en-Y gastric bypass surgery (RYGB) 
Roux-en-Y gastric bypass surgery is a highly effective treatment for severe obesity, especially in 
diabetic patients. Isolation of the proximal small intestine and its luminal glucose sensing capacity 
from nutrients, and the presence of non-digested luminal nutrients in more distal parts of the small 
intestine, is thought to be crucial in the weight-reducing and anti-diabetic effects of surgery; 
although the mechanisms have not been defined. SGLT3b mRNA is expressed differentially along the 
small intestine after RYGB surgery in a rat model (Bhutta et al., 2014). Expression was significantly 
higher in the common limb (distal to the Y-intersection) of both Sprague-Dawley and diabetic ZDF 
rats compared with the biliopancreatic (bypassed portion of stomach and duodenum) and Roux 
(anastomosis of fundal gastric remnant with jejunum) limbs. In contrast, no differential mRNA 
expression was detected for SGLT1, GLUT2, and taste receptor T1R2. Furthermore, saccharin, which 
stimulates taste receptors T1R2/3, infused into the biliopancreatic limb down-regulated expression 
of SGLT3b in the common limb of ZDF rats, though not significantly in Sprague-Dawley rats (Bhutta et 
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al., 2014). The data suggest a possible role for SGLT3 in the post-RYGB intestinal changes. The 
involvement of SGLT3-mediated intraluminal glucose sensing in proximal small intestine has also 
been proposed in a foregut exclusion model resembling RYGB (Pal et al., 2015).  Here the proximal 
duodeno-jejunal part of the intestine was isolated so that different glucose analogues could be 
administered to the excluded segment. At the same time, a glucose bolus was administered to the 
jejunum so that the effect on absorption could be measured. αMDG administration caused 
significantly higher glucose absorption than 3-OMG or saccharin, and this effect was blocked by the 
SGLT1/SGLT3 inhibitor phlorizin. The authors conclude that SGLT3, and not SGLT1 or taste receptors, 
mediates the higher glucose absorption in the RYGB model. Taken together it seems that SGLT3 may 
have a role in the beneficial outcomes of RYGB, although more direct evidence is required.  
 
GLP-1 secretion 
SGLT3 has been thought to play a role in the secretion of the incretin hormone glucagon-like peptide-
1 (GLP-1). In the foregut exclusion model, GLP-1 secretion (measured as the difference between 
portal and systemic concentration) was significantly higher after treatment with the SGLT1/3 agonist 
αMDG, while no difference was detected after treatment with the SGLT1-only agonist 3-OMG (Pal et 
al., 2015), suggesting SGLT3 might mediate GLP-1 secretion. The effect of αMDG was blocked by 
phlorizin and prior vagotomy, supporting SGLT participation and indicating involvement of vagal 
innervation. 
An indirect role for SGLT3 in mediating GLP-1 secretion was proposed recently by Lee et al. (2015). To 
stimulate SGLT3, the authors used miglitol, an iminosugar that is used as an α-glucosidase inhibitor 
and it is a potent agonist of human SGLT3 (Voss et al., 2007; Lee et al., 2015). Miglitol was able to 
activate duodenal enteroendocrine cells more effectively than acarbose, another α-glucosidase 
inhibitor. However, miglitol administration alone failed to increase GLP-1 secretion enough to alter 
plasma concentrations and was only effective when co-administered with maltose. Since no GLP-1 
stimulation was seen after giving acarbose with maltose, it was concluded that miglitol may have a 
direct effect on SGLT3 to stimulate GLP-1 secretion (Lee et al., 2015).  
 
Some controversies and limitations 
Since there is still a lack of suitable tool compounds for studying SGLT3 function directly, so far all 
reports on its likely function in vivo are based on indirect evidence. Several authors (O’Malley et al., 
2006; Delaere et al., 2013; Pal et al., 2015) argue for discrimination between SGLT1 and SGLT3 on the 
basis of differing affinities for αMDG and 3-OMG: αMDG is a substrate for both SGLT1 and SGLT3, 
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whereas 3-OMG is a substrate for SGLT1 only. However, this selectivity is based only on data from pig 
SGLT3 (Diez-Sampedro et al., 2003) and we do not know if it extends to other species. Similarly, the 
putative SGLT3 agonist miglitol was shown to activate human SGLT3 (Voss et al., 2007; Lee et al., 
2015), although evidence for this in rodents is lacking, despite its use in rats (Lee et al., 2015). 
Moreover, some authors have not tried or been able to distinguish between the SGLT3a and SGLT3b 
rodent isoforms in their studies, particularly when using antibodies where its isoform specificity is 
unclear, or they have focused on only one isoform (SGLT3b). 
 
Future perspectives 
A glucose sensing mechanism for SGLT3 has been proposed from in vitro models and based on 
SGLT3’s ability to generate membrane currents in the presence of glucose, Na+ and/or H+. However, 
direct evidence for glucose sensing in vivo is still lacking. Neuronal protein expression has been 
shown in human submucosal/myenteric tissue, and mRNA expression has been detected in scrapped 
mucosa, and by microarray gene expression analysis in enterocytes and enteroendocrine cells. Tissue 
localization of rodent isoforms remains controversial at the protein level, because of antibody 
specificity, and poorly defined mRNA expression. A more definitive examination of SGLT3’s organ and 
tissue distribution is still needed, as well as better selective agonists and antagonists, or its function 
will remain intriguing, but increasingly speculative. Knockout mice for both rodent isoforms have 
been reported from one source to have no obvious phenotype, but they have not been investigated 
in any detail and are not widely available for study.  Emerging technologies such as CRISPR make it 
possible to produce isoform-specific knockout mice or even rats, which in combination with imino 
sugars and specific SGLT inhibitors, should enable us to explore and define better the physiological 
and pathophysiological function of SGLT3, at least in rodents. 
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Table 1. Protein sequence identity matrix of human and rodent sodium glucose transporter (SGLT) isoforms 1, 2, and 3. 
 hSGLT3 mSGLT3a rSGLT3a mSGLT3b rSGLT3b hSGLT1 mSGLT1 rSGLT1 hSGLT2 mSGLT2 rSGLT2
hSGLT3 100.0 79.2 80.3 76.5 76.8 69.6 71.6 71.9 56.5 56.4 55.3
mSGLT3a 79.2 100.0 92.8 75.3 75.0 69.0 70.1 69.7 56.4 56.2 56.3
rSGLT3a 80.3 92.8 100.0 76.4 76.7 69.8 71.5 71.5 56.4 56.1 56.4
mSGLT3b 76.5 75.3 76.4 100.0 90.2 70.4 71.8 71.5 58.4 59.5 57.9
rSGLT3b 76.8 75.0 76.7 90.2 100.0 71.3 72.4 72.3 58.4 58.6 57.3
hSGLT1 69.6 69.0 69.8 70.4 71.3 100.0 88.0 87.8 58.9 60.9 58.9
mSGLT1 71.6 70.1 71.5 71.8 72.4 88.0 100.0 95.8 59.0 60.2 59.5
rSGLT1 71.9 69.7 71.5 71.5 72.3 87.8 95.8 100.0 59.3 60.6 59.8
hSGLT2 56.5 56.4 56.4 58.4 58.4 58.9 59.0 59.3 100.0 91.0 91.2
mSGLT2 56.4 56.2 56.1 59.5 58.6 60.9 60.2 60.6 91.0 100.0 90.1
rSGLT2 55.3 56.3 56.4 57.9 57.3 58.9 59.5 59.8 91.2 90.1 100.0
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Table 2. A comparison of corresponding amino acid residues in putative ligand binding sites and gates. 
 Sugar binding  Na+ binding  Outer gates  Inner 
gates 
 H83 E102 A105 K321 T287 W291 Q457 N78 A76 I79 S389 S392 S393 L87 F101 F453 Y290
hSGLT3 H E S K A W E N  A I S S S  L F I  Y 
mSGLT3a H E S K A W E N  A I S S S  L F V  Y 
rSGLT3a H E S K A W E N  A I S S S  L F I  Y 
mSGLT3b H E A K A W G N A I S S S L V F Y
rSGLT3b H E A K A W S N A I S S S L V F Y
hSGLT1 H E A K T W Q N A I S S S L F F Y
mSGLT1 H E A K A W Q N  A I S S S  L F F  Y 
rSGLT1 H E A K A W Q N  A I S S S  L F F  Y 
hSGLT2 H E A K S W Q N  A I A S S  L F F  Y 
mSGLT2 H E A K S W Q N  A I A S S  L F F  Y 
rSGLT2 H E A K S W Q N  A I A S S  L F F  Y 
conservation * * : * : *  *  * * : * *  * . .  * 
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The conserved ligand binding sites and gates were adopted from alignment of hSGLT1 to vSGLT (Sala-Rabanal et al., 2012). The residue numbering is based 
on hSGLT1 and corresponding residues were obtained by multiple sequence alignment CLUSTAL O (1.2.3). *, fully conserved residue; :, conservation strongly 
similar - scoring > 0.5 in the Gonnet PAM 250 matrix. . (period), conservation weakly similar - scoring =< 0.5 in the Gonnet PAM 250 matrix. Residues in 
SGLT3 different from SGLT1 are in bold. 
 
Table 3. Tissue distribution of different isoforms expression. 
 mRNA protein
 RT-PCR qPCR WB IHC 
human SGLT3 small intestine1, 
colon2, skeletal 
muscle1, kidney cell 
line2,3 
small intestine4,5, 
kidney4,5, adipose5, 
adrenal4, blood vessel5, 
bone4, brain5, heart4,5, 
lung4, ovary5, prostate4, 
skeletal muscle5, 
spleen5, stomach4,5, 
testis4,5, thyroid4, 
trachea4 
small intestine1, kidney3, 
kidney cell line3, skeletal 
muscle1 
small intestine1, skeletal 
muscle1 
mouse SGLT3a small intestine6,7, 
intestinal cell line6,7, 
kidney8 
small intestine9, 
kidney9,10, portal area10 
small intestine10, kidney10, 
liver10, portal area10 
 
mouse SGLT3b small intestine7, 
kidney8, kidney cell 
line11 
small intestine9, 
kidney9,10, portal area10 
small intestine10, kidney10, 
brain12, liver10, portal 
area10 
brain12 
rat SGLT3a small intestine13, 
kidney9, brain13 
small intestine14, colon14  
rat SGLT3b small intestine13, 
brain13 
small intestine15,16   
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1Diez-Sampedro et al., 2003; 2Veyhl et al., 1998; 3Kothinti et al., 2012; 4Nishimura et al., 2005; 5Chen et al., 2010; 6Gribble et al., 2003; 7Lee et al., 2015; 
8Tabatabai et al., 2003; 9Barcelona et al., 2012; 10Delaere et al., 2012; 11Tabatabai et al., 2001; 12Yamazaki et al., 2014; 13O’Malley et al., 2006; 14Freeman et 
al., 2006; 15Bhutta et al., 2014; 16Pal et al., 2015. 
 
Table 4. Table of sodium glucose transporter (SGLT) isoform 3 characteristics and differences 
 hSGLT3 r/mSGLT3a mSGLT3b
Glucose uptake No No Small 
pH sensitivity Yes Yes No
Phlorizin sensitivity Yes No Yes
Glucose/α-MDG-induced 
currents at pH 7.4 
Yes, small No Yes, large 
Glucose/α-MDG-induced 
currents at pH 5 
Yes, large Yes, large Yes, small
H+-induced currents Yes, medium Yes, large No 
Na+ requirement Yes, partial No Yes, partial 
DNJ-induced currents at pH 7.4 Yes No No 
DNJ-induced currents at pH 5 Yes, large Yes n.d.
α-MDG, α-methyl-D-glucose; DNJ, 1-deoxynojirimycin; n.d., not determined, data are not available. Sources: Diez-Sampedro et al., 2003; Voss et al., 2007; 
Aljure & Díez-Sampedro, 2010; Barcelona et al., 2012. 
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